IBDEI1YQ ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,33314,1,4,0)
 ;;=4^L40.0
 ;;^UTILITY(U,$J,358.3,33314,2)
 ;;=^5009160
 ;;^UTILITY(U,$J,358.3,33315,0)
 ;;=L40.1^^131^1669^256
 ;;^UTILITY(U,$J,358.3,33315,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33315,1,3,0)
 ;;=3^Pustulosis Psoriasis,Generalized
 ;;^UTILITY(U,$J,358.3,33315,1,4,0)
 ;;=4^L40.1
 ;;^UTILITY(U,$J,358.3,33315,2)
 ;;=^5009161
 ;;^UTILITY(U,$J,358.3,33316,0)
 ;;=L40.2^^131^1669^11
 ;;^UTILITY(U,$J,358.3,33316,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33316,1,3,0)
 ;;=3^Acrodermatitis Continua
 ;;^UTILITY(U,$J,358.3,33316,1,4,0)
 ;;=4^L40.2
 ;;^UTILITY(U,$J,358.3,33316,2)
 ;;=^5009162
 ;;^UTILITY(U,$J,358.3,33317,0)
 ;;=L40.3^^131^1669^255
 ;;^UTILITY(U,$J,358.3,33317,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33317,1,3,0)
 ;;=3^Pustulosis Palmaris et Plantaris
 ;;^UTILITY(U,$J,358.3,33317,1,4,0)
 ;;=4^L40.3
 ;;^UTILITY(U,$J,358.3,33317,2)
 ;;=^5009163
 ;;^UTILITY(U,$J,358.3,33318,0)
 ;;=L40.4^^131^1669^157
 ;;^UTILITY(U,$J,358.3,33318,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33318,1,3,0)
 ;;=3^Guttate Psoriasis
 ;;^UTILITY(U,$J,358.3,33318,1,4,0)
 ;;=4^L40.4
 ;;^UTILITY(U,$J,358.3,33318,2)
 ;;=^5009164
 ;;^UTILITY(U,$J,358.3,33319,0)
 ;;=L40.8^^131^1669^252
 ;;^UTILITY(U,$J,358.3,33319,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33319,1,3,0)
 ;;=3^Psoriasis NEC
 ;;^UTILITY(U,$J,358.3,33319,1,4,0)
 ;;=4^L40.8
 ;;^UTILITY(U,$J,358.3,33319,2)
 ;;=^271917
 ;;^UTILITY(U,$J,358.3,33320,0)
 ;;=L40.9^^131^1669^254
 ;;^UTILITY(U,$J,358.3,33320,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33320,1,3,0)
 ;;=3^Psoriasis,Unspec
 ;;^UTILITY(U,$J,358.3,33320,1,4,0)
 ;;=4^L40.9
 ;;^UTILITY(U,$J,358.3,33320,2)
 ;;=^5009171
 ;;^UTILITY(U,$J,358.3,33321,0)
 ;;=L50.9^^131^1669^286
 ;;^UTILITY(U,$J,358.3,33321,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33321,1,3,0)
 ;;=3^Urticaria,Unspec
 ;;^UTILITY(U,$J,358.3,33321,1,4,0)
 ;;=4^L50.9
 ;;^UTILITY(U,$J,358.3,33321,2)
 ;;=^5009204
 ;;^UTILITY(U,$J,358.3,33322,0)
 ;;=L53.8^^131^1669^147
 ;;^UTILITY(U,$J,358.3,33322,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33322,1,3,0)
 ;;=3^Erythematous Conditions NEC
 ;;^UTILITY(U,$J,358.3,33322,1,4,0)
 ;;=4^L53.8
 ;;^UTILITY(U,$J,358.3,33322,2)
 ;;=^88044
 ;;^UTILITY(U,$J,358.3,33323,0)
 ;;=L53.9^^131^1669^146
 ;;^UTILITY(U,$J,358.3,33323,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33323,1,3,0)
 ;;=3^Erythematous Condition,Unspec
 ;;^UTILITY(U,$J,358.3,33323,1,4,0)
 ;;=4^L53.9
 ;;^UTILITY(U,$J,358.3,33323,2)
 ;;=^5009210
 ;;^UTILITY(U,$J,358.3,33324,0)
 ;;=L54.^^131^1669^145
 ;;^UTILITY(U,$J,358.3,33324,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33324,1,3,0)
 ;;=3^Erythema in Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,33324,1,4,0)
 ;;=4^L54.
 ;;^UTILITY(U,$J,358.3,33324,2)
 ;;=^5009211
 ;;^UTILITY(U,$J,358.3,33325,0)
 ;;=L56.0^^131^1669^139
 ;;^UTILITY(U,$J,358.3,33325,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33325,1,3,0)
 ;;=3^Drug Phototoxic Response
 ;;^UTILITY(U,$J,358.3,33325,1,4,0)
 ;;=4^L56.0
 ;;^UTILITY(U,$J,358.3,33325,2)
 ;;=^5009214
 ;;^UTILITY(U,$J,358.3,33326,0)
 ;;=L56.1^^131^1669^138
 ;;^UTILITY(U,$J,358.3,33326,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33326,1,3,0)
 ;;=3^Drug Photoallergic Response
 ;;^UTILITY(U,$J,358.3,33326,1,4,0)
 ;;=4^L56.1
 ;;^UTILITY(U,$J,358.3,33326,2)
 ;;=^5009215
 ;;^UTILITY(U,$J,358.3,33327,0)
 ;;=L56.2^^131^1669^236
 ;;^UTILITY(U,$J,358.3,33327,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33327,1,3,0)
 ;;=3^Photocontact Dermatitis
 ;;^UTILITY(U,$J,358.3,33327,1,4,0)
 ;;=4^L56.2
 ;;^UTILITY(U,$J,358.3,33327,2)
 ;;=^5009216
